Deakin University
Browse

File(s) not publicly available

Immunotherapy of cancer by antisense inhibition of Ii protein, an immunoregulator of antigen selection by MHC class II molecules

journal contribution
posted on 2023-05-26, 05:33 authored by MZ Xu, Xuequan Lu, NL Kallinteris, Y Wang, SZ Wu, E von Hofe, JV Gulfo, RE Humphreys, GG Hillman
Ii protein suppression is a promising antisense drug-based therapy that dramatically enhances the immunogenicity of tumor cell major histocompatibility complex class II-presented antigenic epitopes. The strength of this approach is that the antisense only needs to be transiently effective in a fraction of the tumor cells. The systemic antitumor immune response generated subsequently eradicates both directly treated cells and distant tumor deposits. The drugs and mechanisms of this therapy are considered, in addition to practical developmental questions.

History

Journal

CURRENT OPINION IN MOLECULAR THERAPEUTICS

Volume

6

Pagination

160-165

Location

England

ISSN

1464-8431

eISSN

2040-3445

Language

English

Issue

2

Publisher

THOMSON REUTERS (SCIENTIFIC) LTD